PAX3 and breast carcinoma: To investigate the status of CDHs in breast cancer, we screened 27 members of CDHs in TCGA datasets and found that CDH1 was indeed low expressed or mutated in 16% of TCGA samples, and other CDHs (especially CDH17, CDH4, CDH26, CDH3/8, and CDH2/6/12) were almost highly expressed or amplified (Supplementary Figure  S1 in Supplementary Material at https://doi.org/10.1155/2017/5091541).